Infectious Disease Diagnostics Market | North America Market is Expected to Grow at the Fastest Rate

According to the new market research report “ Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast”, published by MarketsandMarkets™

• The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

What Drives the Market?

1. Increasing global prevalence of infectious diseases
2. Shift in focus from centralized laboratories to decentralized point-of-care testing
3. Growth in funding for research on infectious disease diagnostics

The global prevalence of infectious diseases such as influenza, HPV, hepatitis, HIV, and tuberculosis is considerably high in spite of significant improvements in sanitation practices and medicine. Many of the currently available diagnostic techniques are slow, involve complex procedures, and lack specific identification of causative agents.

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some key players mentioned in the research report are:

Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Get Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

Infectious Disease Diagnostics Market Worth $19.35 Billion by 2022 | North America Market is Expected to Grow at the Fastest Rate

Growth in Infectious Disease Diagnostics Market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

What the Market Looks Like?

• The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to   reach $19.35 Billion in 2022, at a CAGR of 5.6%.

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.
 

Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

On the basis of disease type, the infectious disease diagnostics (IDD) market is segmented into a wide range of diseases. Hospital acquired infections (HAI) segment to record the highest CAGR during the forecast period. Growth in HAI segment can be attributed to the rising burden of MRSA infections, the increasing number of new products launched in the market, and increasing adoption of technologically advanced HAI diagnostic tests such as BD MAX Cdiff assay, Xpert MRSA NxG, and ARIES C. difficile Assay that are based on PCR technology

What Drives the Market?

The growth of the global market for infectious disease diagnostics market is primarily influenced by the following factors:

1. Increasing Global Prevalence of Infectious Diseases
2. Shift in Focus From Centralized Laboratories to Decentralized Point-Of-Care Testing
3. Growth in Funding for Research on Infectious Disease Diagnostics

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

Read more about infectious disease diagnostics market @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

The geographical regions mapped in the report are:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

North America accounted for the largest share of the global infectious disease diagnostics market. The large share of this region is mainly attributed to the presence of a highly developed healthcare system, increasing prevalence of infectious diseases, the presence of a large number of leading national clinical laboratories, and easy accessibility to technologically advanced instruments in the region.

Some key players mentioned in the research report are:

Abbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Infectious Disease Diagnostics Market and Increasing Global Prevalence of Infectious Diseases

 Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022

The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

                  

The Infectious Disease Diagnostics Market is Segmented on:

1. Product & Service
2. Disease Type
3. Technology
4. End User

By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

By technology, DNA sequencing & next-generation sequencing (NGS) segment to record the highest CAGR during the forecast period

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Critical questions the report answers:

• Where will all these developments take the industry in the long term?
• What are the upcoming trends for the infectious disease diagnostics market?
• Which segment provides the most opportunity for growth?
• Who are the leading vendors operating in this market?
• What are the opportunities for new market entrants?

Key Market Players

The prominent players in this market areAbbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Vaccine Adjuvants Market : Future of biotechnology , it is Creating Real Change in the biotechnology Industry

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants.

Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

                         
Global Vaccine Adjuvants Market Segmentation:

The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

+ On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period.

+ On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016.

+ On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

What Drives the Market?

1. Increasing Use of Adjuvants in Vaccine
2. High Prevalence of Infectious and Zoonotic Diseases
3. Increase in Livestock and Instances of Diseases
4. Increasing Focus on Immunization Programs From Various Government Bodies
5. Technological Advancements in Aluminum Hydroxide-Based Adjuvants
6. Increasing Focus and Support on the Discovery and Development of Vaccine Adjuvants
7. Increasing Geriatric Population

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

Geographical Growth Analysis:

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.

Vaccine Adjuvants Market | Analysis of Worldwide Industry Trends and Opportunities

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

                  

What Drives the Market?

1. Increasing Use of Adjuvants in Vaccine
2. High Prevalence of Infectious and Zoonotic Diseases
3. Increase in Livestock and Instances of Diseases
4. Increasing Focus on Immunization Programs From Various Government Bodies
5. Technological Advancements in Aluminum Hydroxide-Based Adjuvants
6. Increasing Focus and Support on the Discovery and Development of Vaccine Adjuvants
7. Increasing Geriatric Population

Global Vaccine Adjuvants Market Segmentation:

The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

+ On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period.

+ On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016.

+ On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

Geographical Growth Analysis:

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.

Useful Analysis from Experts on Vaccine Adjuvants Market

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.
On the basis of product type, the market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and other adjuvants.

Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894



Global Vaccine Adjuvants Market Segmentation:
The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

+ On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period.

+ On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016.

+ On the basis of disease type, the vaccine adjuvants market is segmented into infectious diseases, cancer, and others. The infectious diseases segment is expected to account for the largest share of the global market in 2016. Factors such as high prevalence of infectious diseases, government & company initiatives, and high prevalence of cancer cases are expected to drive market growth in the coming years.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

What Drives the Market?

1. Increasing Use of Adjuvants in Vaccine
2. High Prevalence of Infectious and Zoonotic Diseases
3. Increase in Livestock and Instances of Diseases
4. Increasing Focus on Immunization Programs From Various Government Bodies
5. Technological Advancements in Aluminum Hydroxide-Based Adjuvants
6. Increasing Focus and Support on the Discovery and Development of Vaccine Adjuvants
7. Increasing Geriatric Population

Geographical Growth Analysis:

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.

Key Players and Strategies Adopted by Them:

The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=152603894